We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for venetoclax (Abbvie Pty Ltd)
Active ingredients
venetoclax
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet, film-coated
Indication
Venetoclax is indicated for the treatment of patients with acute myeloid leukaemia (AML)
Therapeutic area
Haematology